Skip to main content
OpenTrials
Completed

NCT Number: NCT03033420

Reducing the Rate and Duration of Re-ADMISsions Among Patients With Unipolar Disorder and Bipolar Disorder Using Smartphone-based Monitoring and Treatment - The RADMIS Trials

Unipolar and bipolar disorder combined account for nearly half of all morbidity and mortality due to mental and substance use disorders, and burden society with the highest health care costs of all psychiatric and neurological disorders. Among these, costs due to psychiatric hospitalization is a major burden. Smartphones comprise an innovative and unique platform for monitoring and treatment of depression and mania.

The RADMIS trials use a randomized controlled single-blind parallel-group design. Patients with unipolar or bipolar disorder discharged from psychiatric hospitals in The Capital Region of Denmark are invited to participate. Patients are at discharge from the psychiatric hospitals randomized, separately according to psychiatric diagnosis (thus, the RADMIS trial consists of two separate trials according to diagnosis, bipolar disorder or unipolar disorder), to: 1) a smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules (intervention group) or 2) treatment-as-usual (control group) for a 6-months trial period. The trial is started in March 2017. The outcomes are 1) differences in the number and duration of re-admissions between the intervention group and the control group (primary), 2) differences in severity of depressive and manic symptoms (manic symptoms only for patients with bipolar disorder); differences in psychosocial functioning; and differences in number of affective episodes between the intervention group and the control group (secondary), and 3) differences in perceived stress, quality of life, self-rated depressive symptoms, self-rated manic symptoms (only for patients with bipolar disorder), recovery, empowerment, adherence to medication, well-being, ruminations, worrying, and satisfaction between the intervention group and the control group (tertiary).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Psychiatric Center Copenhagen, Rigshospitalet

Copenhagen, 2100, Denmark

About this study

Background Unipolar and bipolar disorder combined account for nearly half of all morbidity and mortality due to mental and substance use disorders, and burden society with the highest health care costs of all psychiatric and neurological disorders. Among these, costs due to psychiatric hospitalization are a major burden. Smartphones comprise an innovative and unique platform for monitoring and treatment of depression and mania. No prior trial has investigated whether the use of a smartphone-based system can prevent re-admission among patients discharged from hospital.

Methods The RADMIS trials use a randomized controlled single-blind parallel-group design. Patients with unipolar disorder and patients with bipolar disorder are invited to participate in each their trial when discharged from psychiatric hospitals in The Capital Region of Denmark following an affective episode and randomized to either 1) a smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules (intervention group) or 2) standard treatment (control group) for a 6-months trial period. The trial is started in March 2017. The outcomes are 1) differences in the number and duration of re-admissions between the intervention group and the control group (primary), 2) differences in severity of depressive and manic symptoms (manic symptoms only for patients with bipolar disorder); differences in psychosocial functioning; and differences in number of affective episodes between the intervention group and the control group (secondary), and 3) differences in perceived stress, quality of life, self-rated depressive symptoms, self-rated manic symptoms (only for patients with bipolar disorder), recovery, empowerment, adherence to medication, well-being, ruminations, worrying, and satisfaction between the intervention group and the control group (tertiary).

Analysis Recruitment is ongoing.

Discussion If the smartphone-based monitoring system is proved effective in reducing the rate and duration of re-admissions there will be basis for using a system of this kind in the treatment of unipolar and bipolar disorder in general and in a larger scale.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Unipolar disorder or bipolar disorder diagnoses according to ICD-10
  • Patients who are discharged from a psychiatric hospital in The Capital Region of Denmark following an affective episode (depression or mania)

Exclusion criteria

  • Pregnancy
  • A lack of Danish language skills

Treatment and study plan

A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules

Device

A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules

Other names: Monsenso

Primary outcomes

  1. Number of re-admissions

    Time frame: 6 months trial period

    Differences in the number of re-admissions between the intervention group and the control group. Data will be collected from Danish registers.

  2. Duration of re-admissions

    Time frame: 6 months trial period

    Differences in the duration of re-admissions between the intervention group and the control group.

Secondary outcomes

  1. Severity of depressive symptoms

    Time frame: 6 months trial period

    Differences in the severity of depressive (The Hamilton Depression Rating Scale) symptoms between the intervention group and the control group.

  2. Severity of manic symptoms

    Time frame: 6 months trial period

    Differences in the severity of manic (The Young Mania Rating Scale) symptoms between the intervention group and the control group.

  3. Psychosocial functioning

    Time frame: 6 months trial period

    Differences in psychosocial functioning (The Psychosocial Functioning Assessment Short Test - FAST) between the intervention group and the control group.

  4. Number of affective episodes

    Time frame: 6 months trial period

    Differences in the number of affective episodes between the intervention group and the control group.

Other outcomes

  1. Perceived stress

    Time frame: 6 months trial period

    Differences in perceived stress (The Cohen's Perceived stress scale) between the intervention group and the control group.

  2. Quality of life

    Time frame: 6 months trial period

    Differences in quality of life (The WHO Quality of Life-BREF) between the intervention group and the control group.

  3. Self-rated manic symptoms

    Time frame: 6 months trial period

    Differences in self-rated manic symptoms (The Altman Self Rating scale for Mania) between the intervention group and the control group.

  4. Self-rated depressive symptoms

    Time frame: 6 months trial period

    Differences in self-rated depressive symptoms (The Becks Depressive Inventory) between the intervention group and the control group.

  5. Self-rated depressive symptoms

    Time frame: 6 months trial period

    Differences in self-rated depressive symptoms (The Hamilton Depression Self-rating Scale 6-item) between the intervention group and the control group.

  6. Recovery

    Time frame: 6 months trial period

    Differences in recovery (The Recovery Assessment Scale) between the intervention group and the control group.

  7. Empowerment

    Time frame: 6 months trial period

    Differences in empowerment (Rogers empowerment scale) between the intervention group and the control group.

  8. Adherence to medication

    Time frame: 6 months trial period

    Differences in adherence to medication (The Medicine Adherence Rating Scale) between the intervention group and the control group.

  9. Well-being

    Time frame: 6 months trial period

    Differences in well-being according (The WHO (five) well-being index) between the intervention group and the control group.

  10. Rumination

    Time frame: 6 months trial period

    Differences in rumination (The Rumination Response Scale) between the intervention group and the control group.

  11. Worrying

    Time frame: 6 months trial period

    Differences in worrying (The Penn State Worry Questionnaire) between the intervention group and the control group.

  12. Satisfaction

    Time frame: 6 months trial period

    Differences in satisfaction (The Verona Satisfaction Scale-Affective Disorder) between the intervention group and the control group.

Sponsors and collaborators

Lead sponsor

Psychiatric Centre Rigshospitalet

Other

Collaborators

  • Technical University of Denmark

Registry information

Acronym: RADMIS

Important dates

Study start
2017
Primary completion
2020
Study completion
2021
First posted
Jan 26, 2017
Registry last updated
Sep 29, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.